clinical trial · NCT00647816
Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg
HealthyPropranolol Hydrochloride Extended-Release Capsules 160 mgInderal® LA Capsules 160 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's propranolol hydrochloride extended-release 160 mg capsules to Wyeth's Inderal LA® 160 mg capsules following a single, oral 160 mg (1 x 160 mg) dose administration under fasting conditions.
started
Sep 1, 2005
primary completion
Sep 1, 2005
completion
Sep 1, 2005
last updated
Apr 24, 2024
official title
Single-Dose Fasting Bioequivalence Study of Propranolol Hydrochloride Extended-Release Capsules (160 mg; Mylan) and Inderal® LA Capsules (160 mg; Wyeth) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol